Dr. Jerry Shapiro is a leading expert in hair disorders and an authority on hair transplant surgeries. He was the president of the World Congress of Dermatology in 2015, and has been a speaker at the American Academy of Dermatology for over 30 years. He has published numerous articles and has also authored and co-authored dermatology textbooks and has appearances in national and international radio and TV shows. Dr. Shapiro currently practices in New York, at the NYU Langone Medical Centre.
STL Index for: Jerry Shapiro
Androgenetic Alopecia: A Review of Topical Agents for Hair Growth Promotion (Pharmacist)
Hair loss is a common dermatological problem that affects a large segment of the population both physically and psychologically. Currently, only one topical agent is approved for treatment of hair loss in men, although other treatments are being clinically investigated.
Topical Agents for Hair Growth Promotion: What Is Out There?
Hair loss is a widespread complaint that carries a significant psychosocial burden for affected individuals. Androgenetic alopecia (AGA) is the predominant cause of hair loss seen in the dermatology clinic. This article reviews a range of therapies that are available for AGA treatment.
Androgenetic Alopecia: A Review of Topical Agents for Hair Growth Promotion (Family Practice)
Hair loss is a common dermatological problem that affects a large segment of the population both physically and psychologically. This article focuses on androgenetic alopecia (AGA) or male pattern hair loss, as well as the common treatments, Minoxidil and other topical treatments.
Promising Therapies for Treating and/or Preventing Androgenic Alopecia
Androgenetic alopecia (AGA) may affect up to 70% of men and 40% of women at some point in their lifetime. Here we briefly review current therapeutic options and treatments under active investigation.
Management of Hirsutism
Hirsutism is a relatively common condition affecting about 5%-10% of women of childbearing age. Herein, we present an overview of hirsutism with emphasis on its etiology and therapeutic options.
Treatments for Unwanted Facial Hair
Twenty-two percent of women in North America have unwanted facial hair, which can cause embarrassment and result in a significant emotional burden. Eflornithine 13.9% cream can be used in combination with other treatments such as lasers and IPL to give the patient the best chance for successful hair removal.
Excessive Facial Hair
Hirsutism can cause embarrassment and lead to anxiety and depression. There are a limited number of treatments available that vary in efficacy, degree of discomfort and cost. It is very important to make sure that the patient is aware of all the available treatment modalities, since no one method is effective for all patients or body locations, and results from therapy may not always be satisfactory.
Once Daily Application of a Combination of Calcipotriol and Betamethasone Dipropionate (Dovobet®, Daivobet®) for the Treatment of Psoriasis
This new compound product containing 50µg/gm calcipotriol and 0.5mg/gm betamethasone dipropionate was recently introduced in Canada for the treatment of psoriasis. Clinical trials demonstrated that this compound was more active than either agent used alone.
Vaniqa – Eflornithine 13.9% Cream
Eflornithine HCl 13.9% cream (Vaniqa) is the first topical prescription treatment to be approved for the reduction of unwanted facial hair in women. It irreversibly inhibits ornithine decarboxylase, an enzyme that catalyzes the ratelimiting step for follicular polyamine synthesis, which is necessary for hair growth.
